Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620130 | 0.88 | HPGDS (0.39) | MCHR1SLC2A1HTR7KCNH2 | |
| SCHEMBL619997 | 0.86 | KCNH2 (0.39) | HTR7KCNH2 | |
| SCHEMBL620931 | 0.84 | KCNH2 (0.44) | HTR7HTR1ADRD2HTR6KCNH2 | |
| SCHEMBL621354 | 0.83 | MCHR1 (0.40) | MCHR1SLC2A1HTR7KCNH2 | |
| SCHEMBL619473 | 0.82 | MCHR1 (0.40) | MCHR1SLC2A1HTR7KDM4EALDH1A1 | |
| SCHEMBL622311 | 0.79 | GSK3B (0.42) | HTR7 | |
| SCHEMBL620405 | 0.77 | HPGD (0.47) | MCHR1DRD4ALDH1A1HPGDKCNH2 | |
| SCHEMBL622214 | 0.77 | HTR7 (0.37) | HTR7DRD2KCNH2 | |
| SCHEMBL619404 | 0.74 | HPGD (0.47) | MCHR1DRD4ALDH1A1HPGDKCNH2 | |
| SCHEMBL622377 | 0.73 | HPGDS (0.40) | HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | MCHR1 533/4885SLC2A1 3075/4885DRD4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.